Eton Pharmaceuticals (ETON) Financials

$20.04 +0.23 (+1.16%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$20.52 +0.48 (+2.42%)

As of 04:03 AM Eastern

Annual Income Statements for Eton Pharmaceuticals

This table shows Eton Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-3.82	-0.94	-9.02
Consolidated Net Income / (Loss)	-3.82	-0.94	-9.02
Net Income / (Loss) Continuing Operations	-3.82	-0.94	-9.02
Total Pre-Tax Income	-3.81	-0.69	-9.02
Total Operating Income	-2.60	-1.19	-8.26
Total Gross Profit	23	21	14
Total Revenue	39	32	21
Operating Revenue	39	32	21
Total Cost of Revenue	16	11	6.93
Operating Cost of Revenue	16	11	6.93
Total Operating Expenses	26	22	23
Selling, General & Admin Expense	23	19	19
Research & Development Expense	3.26	3.32	4.00
Total Other Income / (Expense), net	-1.21	0.50	-0.76
Other Income / (Expense), net	-1.21	0.50	-0.76
Income Tax Expense	0.02	0.25	0.00
Basic Earnings per Share	($0.15)	($0.04)	($0.36)
Weighted Average Basic Shares Outstanding	25.90M	25.65M	25.15M
Weighted Average Diluted Shares Outstanding	26.82M	25.69M	25.46M
Weighted Average Basic & Diluted Shares Outstanding	26.82M	25.69M	25.46M

This table shows Eton Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.60	0.63	-3.04	-0.81	-2.26	-0.58	4.56	-2.66	0.91	-3.05
Consolidated Net Income / (Loss)	-0.60	0.63	-3.04	-0.81	-2.26	-0.58	4.56	-2.66	0.91	-3.05
Net Income / (Loss) Continuing Operations	-0.60	0.63	-3.04	-0.81	-2.26	-0.58	4.56	-2.66	0.91	-3.05
Total Pre-Tax Income	-0.51	0.50	-2.99	-0.81	-2.01	-0.58	4.56	-2.66	0.91	-3.05
Total Operating Income	0.63	0.51	-2.94	-0.80	-1.99	-0.55	3.88	-2.53	1.06	-2.90
Total Gross Profit	6.48	6.30	5.63	5.01	3.63	4.40	9.68	3.35	6.36	2.02
Total Revenue	12	10	9.07	7.97	7.31	7.03	12	5.30	8.50	3.22
Operating Revenue	12	10	9.07	7.97	7.31	7.03	12	5.30	8.50	3.22
Total Cost of Revenue	5.17	4.02	3.45	2.96	3.68	2.63	2.32	1.96	2.14	1.20
Operating Cost of Revenue	5.17	4.02	3.45	2.96	3.68	2.63	2.32	1.96	2.14	1.20
Total Operating Expenses	5.85	5.79	8.56	5.81	5.62	4.95	5.80	5.88	5.30	4.91
Selling, General & Admin Expense	6.72	5.29	5.59	5.16	4.58	4.34	4.67	5.35	4.35	4.17
Research & Development Expense	-0.87	0.51	2.97	0.65	1.05	0.62	1.13	0.54	0.94	0.74
Total Other Income / (Expense), net	-1.14	-0.01	-0.05	-0.01	-0.02	-0.03	0.68	-0.13	-0.15	-0.15
Other Income / (Expense), net	-1.21	0.00	0.00	0.00	-0.30	0.00	0.80	0.00	-0.52	0.00
Income Tax Expense	0.09	-0.13	0.05	0.00	0.25	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	($0.02)	$0.02	($0.12)	($0.03)	($0.10)	($0.02)	$0.18	($0.10)	$209.82	($0.12)
Weighted Average Basic Shares Outstanding	25.90M	25.90K	25.78M	25.76M	25.65M	25.72K	25.59M	25.53M	25.15M	25.37M
Weighted Average Diluted Shares Outstanding	26.82M	26.55K	25.78M	25.76M	25.69M	25.72K	25.98M	25.53M	25.46M	25.37M
Weighted Average Basic & Diluted Shares Outstanding	26.82M	25.84M	25.84M	25.69M	25.69M	25.66M	25.65M	25.50M	25.46M	25.30M

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-6.45	5.08	1.90
Net Cash From Operating Activities	0.97	6.82	4.82
Net Cash From Continuing Operating Activities	0.97	6.75	4.82
Net Income / (Loss) Continuing Operations	-3.82	-0.94	-9.02
Consolidated Net Income / (Loss)	-3.82	-0.94	-9.02
Depreciation Expense	1.15	0.90	1.77
Amortization Expense	1.11	0.12	0.13
Non-Cash Adjustments To Reconcile Net Income	6.47	5.96	5.05
Changes in Operating Assets and Liabilities, net	-3.94	0.71	6.89
Net Cash From Investing Activities	-40	-0.78	-2.79
Net Cash From Continuing Investing Activities	-40	-0.78	-2.79
Purchase of Property, Plant & Equipment	-0.03	0.00	-0.04
Acquisitions	-40	-0.78	-2.75
Net Cash From Financing Activities	33	-0.96	-0.13
Net Cash From Continuing Financing Activities	33	-0.96	-0.13
Repayment of Debt	-1.16	-1.16	-0.39
Issuance of Debt	25	0.00	0.00
Issuance of Common Equity	7.25	0.23	0.17
Other Financing Activities, net	1.19	-0.03	0.08
Cash Interest Paid	0.67	0.84	0.73
Cash Income Taxes Paid	0.08	0.25	0.00

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-5.33	2.57	1.04	-4.73	-0.68	0.50	6.86	-1.60	2.93	-3.67
Net Cash From Operating Activities	-0.77	2.95	1.26	-2.47	0.39	0.87	7.10	-1.55	2.84	-1.70
Net Cash From Continuing Operating Activities	-0.77	2.95	1.26	-2.47	0.32	0.87	7.10	-1.55	2.84	-1.70
Net Income / (Loss) Continuing Operations	-0.60	0.63	-3.04	-0.81	-2.26	-0.58	4.56	-2.66	0.91	-3.05
Consolidated Net Income / (Loss)	-0.60	0.63	-3.04	-0.81	-2.26	-0.58	4.56	-2.66	0.91	-3.05
Depreciation Expense	0.36	0.28	0.26	0.25	0.33	0.19	0.17	0.21	0.25	0.17
Amortization Expense	1.04	0.02	0.02	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Non-Cash Adjustments To Reconcile Net Income	-0.38	5.16	0.88	0.82	1.18	3.08	0.82	0.87	1.72	0.95
Changes in Operating Assets and Liabilities, net	-1.18	-3.13	3.14	-2.76	1.05	-1.85	1.52	-0.00	-0.07	0.19
Net Cash From Investing Activities	-38	-	-	-1.88	-0.78	-	-	0.00	-0.01	-2.00
Net Cash From Continuing Investing Activities	-38	-	-	-1.88	-0.78	-	-	0.00	-0.01	-2.00
Purchase of Property, Plant & Equipment	-0.01	-	-	-0.01	-	-	-	0.00	-0.01	-
Acquisitions	-38	-	-	-1.87	-0.78	-	-	0.00	-	-2.00
Net Cash From Financing Activities	34	-0.39	-0.22	-0.38	-0.29	-0.37	-0.25	-0.05	0.10	0.04
Net Cash From Continuing Financing Activities	34	-0.39	-0.22	-0.38	-0.29	-0.37	-0.25	-0.05	0.10	0.04
Other Financing Activities, net	1.02	-	0.17	0.01	-0.14	0.02	0.14	-0.05	-0.07	0.04
Cash Interest Paid	0.14	0.16	0.17	0.19	0.20	0.21	0.21	0.22	0.19	0.17
Cash Income Taxes Paid	-0.10	0.18	-	0.00	0.25	-	-	0.00	-	-

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	76	32	25
Total Current Assets	41	27	20
Cash & Equivalents	15	21	16
Accounts Receivable	5.36	3.41	1.85
Inventories, net	15	0.91	0.56
Prepaid Expenses	5.49	1.13	1.29
Plant, Property, & Equipment, net	0.03	0.06	0.07
Total Noncurrent Assets	35	4.84	4.95
Intangible Assets	35	4.74	4.75
Other Noncurrent Operating Assets	0.19	0.10	0.20
Total Liabilities & Shareholders' Equity	76	32	25
Total Liabilities	52	16	12
Total Current Liabilities	20	16	6.46
Short-Term Debt	0.00	5.38	1.03
Accounts Payable	4.17	1.85	1.77
Accrued Expenses	16	9.01	3.66
Total Noncurrent Liabilities	32	0.02	5.49
Long-Term Debt	30	0.00	5.38
Other Noncurrent Operating Liabilities	1.94	0.02	0.11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	24	15	13
Total Preferred & Common Equity	24	15	13
Total Common Equity	24	15	13
Common Stock	132	120	116
Retained Earnings	-108	-104	-103

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	36	32	31	32	31	24	22
Total Current Assets	30	25	24	27	26	19	16
Cash & Equivalents	20	18	17	22	22	15	13
Accounts Receivable	5.59	4.87	4.24	3.50	3.08	2.87	1.50
Inventories, net	1.94	2.07	2.32	1.05	0.82	0.44	0.48
Prepaid Expenses	1.96	0.80	1.05	0.54	0.87	1.10	1.06
Plant, Property, & Equipment, net	0.03	0.05	0.06	0.04	0.05	0.06	0.07
Total Noncurrent Assets	6.06	6.34	6.47	4.33	4.55	4.75	5.03
Intangible Assets	5.85	6.12	6.39	4.21	4.39	4.57	4.97
Other Noncurrent Operating Assets	0.21	0.22	0.09	0.12	0.16	0.18	0.05
Total Liabilities & Shareholders' Equity	36	32	31	32	31	24	22
Total Liabilities	20	18	15	15	14	13	10
Total Current Liabilities	20	18	15	10	9.59	7.49	4.66
Short-Term Debt	4.13	4.66	5.02	1.54	1.54	1.34	0.71
Accounts Payable	2.68	2.13	2.26	1.71	2.30	1.23	1.05
Accrued Expenses	13	11	8.02	7.14	5.75	4.92	2.90
Total Noncurrent Liabilities	0.13	0.15	0.00	4.24	4.62	5.19	5.68
Other Noncurrent Operating Liabilities	0.13	0.15	0.00	0.04	0.07	0.09	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16	13	15	17	17	11	11
Total Preferred & Common Equity	16	13	15	17	17	11	11
Total Common Equity	16	13	15	17	17	11	11
Common Stock	123	121	120	119	118	117	115
Retained Earnings	-107	-108	-105	-102	-101	-106	-104

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	23.29%	48.90%	-2.66%
EBITDA Growth	-572.04%	104.62%	-316.37%
EBIT Growth	-452.69%	92.36%	-288.84%
NOPAT Growth	-117.87%	85.57%	-452.51%
Net Income Growth	-308.44%	89.62%	-361.43%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-85.78%	41.36%	202.12%
Free Cash Flow Firm Growth	-1,542.94%	209.72%	109.49%
Invested Capital Growth	7,501.69%	-116.65%	-67.79%
Revenue Q/Q Growth	12.50%	-3.61%	12.76%
EBITDA Q/Q Growth	63.91%	-89.37%	-5.75%
EBIT Q/Q Growth	30.96%	-132.12%	-5.81%
NOPAT Q/Q Growth	50.24%	-144.79%	-3.15%
Net Income Q/Q Growth	30.25%	-141.94%	-1.43%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-54.31%	-26.47%	253.73%
Free Cash Flow Firm Q/Q Growth	-1,317.07%	-47.45%	109.14%
Invested Capital Q/Q Growth	25,456.77%	-194.99%	-23.85%
Profitability Metrics	-	-	-
Gross Margin	60.01%	66.56%	67.38%
EBITDA Margin	-3.98%	1.04%	-33.50%
Operating Margin	-6.66%	-3.77%	-38.87%
EBIT Margin	-9.76%	-2.18%	-42.45%
Profit (Net Income) Margin	-9.80%	-2.96%	-42.45%
Tax Burden Percent	100.39%	135.85%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-9.38%	-62.76%	-88.32%
ROIC Less NNEP Spread (ROIC-NNEP)	344.57%	-61.98%	-51.54%
Return on Net Nonoperating Assets (RNNOA)	-9.78%	56.20%	29.56%
Return on Equity (ROE)	-19.16%	-6.56%	-58.75%
Cash Return on Invested Capital (CROIC)	-105.98%	0.00%	14.24%
Operating Return on Assets (OROA)	-7.06%	-2.43%	-34.37%
Return on Assets (ROA)	-7.09%	-3.30%	-34.37%
Return on Common Equity (ROCE)	-19.16%	-6.56%	-58.75%
Return on Equity Simple (ROE_SIMPLE)	-15.65%	-6.05%	-68.98%
Net Operating Profit after Tax (NOPAT)	-1.82	-0.83	-5.78
NOPAT Margin	-4.66%	-2.64%	-27.21%
Net Nonoperating Expense Percent (NNEP)	-353.95%	-0.78%	-36.78%
Return On Investment Capital (ROIC_SIMPLE)	-3.35%	-4.00%	-29.66%
Cost of Revenue to Revenue	39.99%	33.44%	32.62%
SG&A Expenses to Revenue	58.32%	59.83%	87.44%
R&D to Revenue	8.34%	10.50%	18.80%
Operating Expenses to Revenue	66.67%	70.33%	106.24%
Earnings before Interest and Taxes (EBIT)	-3.81	-0.69	-9.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.55	0.33	-7.12
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	14.09	7.26	5.45
Price to Tangible Book Value (P/TBV)	0.00	10.47	8.57
Price to Revenue (P/Rev)	8.82	3.55	3.36
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.13	0.00	19.26
Enterprise Value to Revenue (EV/Rev)	9.20	3.05	2.89
Enterprise Value to EBITDA (EV/EBITDA)	0.00	292.94	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	370.50	14.14	12.75
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	33.39	65.93
Leverage & Solvency	-	-	-
Debt to Equity	1.22	0.35	0.49
Long-Term Debt to Equity	1.22	0.00	0.41
Financial Leverage	-0.03	-0.91	-0.57
Leverage Ratio	2.70	1.99	1.71
Compound Leverage Factor	2.70	1.99	1.71
Debt to Total Capital	54.96%	25.79%	32.92%
Short-Term Debt to Total Capital	0.00%	25.79%	5.30%
Long-Term Debt to Total Capital	54.96%	0.00%	27.62%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	45.04%	74.21%	67.08%
Debt to EBITDA	-19.20	16.35	-0.90
Net Debt to EBITDA	-9.58	-48.66	1.39
Long-Term Debt to EBITDA	-19.20	0.00	-0.76
Debt to NOPAT	-16.40	-6.45	-1.11
Net Debt to NOPAT	-8.18	19.19	1.71
Long-Term Debt to NOPAT	-16.40	0.00	-0.93
Altman Z-Score	2.69	0.88	-1.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.06	1.65	3.10
Quick Ratio	1.02	1.53	2.81
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-42	2.89	0.93
Operating Cash Flow to CapEx	3,726.92%	0.00%	12,686.84%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.72	1.11	0.81
Accounts Receivable Turnover	8.89	12.02	5.80
Inventory Turnover	1.93	14.42	12.53
Fixed Asset Turnover	848.07	486.80	227.28
Accounts Payable Turnover	5.19	5.86	3.92
Days Sales Outstanding (DSO)	41.04	30.36	62.89
Days Inventory Outstanding (DIO)	188.85	25.32	29.14
Days Payable Outstanding (DPO)	70.37	62.33	93.18
Cash Conversion Cycle (CCC)	159.52	-6.66	-1.16
Capital & Investment Metrics	-	-	-
Invested Capital	39	-0.53	3.19
Invested Capital Turnover	2.01	23.80	3.25
Increase / (Decrease) in Invested Capital	40	-3.72	-6.71
Enterprise Value (EV)	359	96	61
Market Capitalization	344	112	71
Book Value per Share	$0.95	$0.60	$0.52
Tangible Book Value per Share	($0.40)	$0.42	$0.33
Total Capital	54	21	19
Total Debt	30	5.38	6.42
Total Long-Term Debt	30	0.00	5.38
Net Debt	15	-16	-9.89
Capital Expenditures (CapEx)	0.03	0.00	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.14	-5.41	-1.73
Debt-free Net Working Capital (DFNWC)	21	16	15
Net Working Capital (NWC)	21	11	14
Net Nonoperating Expense (NNE)	2.01	0.10	3.24
Net Nonoperating Obligations (NNO)	15	-16	-9.89
Total Depreciation and Amortization (D&A)	2.26	1.02	1.90
Debt-free, Cash-free Net Working Capital to Revenue	15.73%	-17.10%	-8.14%
Debt-free Net Working Capital to Revenue	54.02%	50.50%	68.59%
Net Working Capital to Revenue	54.02%	33.49%	63.73%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.04)	($0.36)
Adjusted Weighted Average Basic Shares Outstanding	25.90M	25.65M	25.15M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	26.82M	25.69M	25.46M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.82M	25.69M	25.46M
Normalized Net Operating Profit after Tax (NOPAT)	-1.82	-0.83	-5.78
Normalized NOPAT Margin	-4.66%	-2.64%	-27.21%
Pre Tax Income Margin	-9.76%	-2.18%	-42.45%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	59.26%	46.90%	-24.36%	50.19%	-13.94%	118.33%	63.05%	143.75%	39.47%	315.35%
EBITDA Growth	141.90%	346.65%	-154.25%	77.18%	-334.34%	87.83%	3,615.83%	55.17%	-31.88%	54.87%
EBIT Growth	74.59%	192.88%	-162.67%	68.43%	-520.96%	81.07%	449.48%	52.46%	-47.64%	52.49%
NOPAT Growth	131.56%	266.06%	-152.91%	68.43%	-231.37%	81.07%	513.97%	50.19%	-19.18%	50.49%
Net Income Growth	73.49%	208.29%	-166.70%	69.51%	-347.37%	80.99%	392.62%	50.09%	-12.22%	50.03%
EPS Growth	0.00%	200.00%	-166.67%	70.00%	0.00%	83.33%	400.00%	0.00%	0.00%	50.00%
Operating Cash Flow Growth	-297.67%	238.14%	-82.33%	-59.75%	-86.37%	151.26%	188.62%	-226.57%	155.50%	42.27%
Free Cash Flow Firm Growth	-1,793.70%	-58.38%	-123.70%	-437.71%	-70.09%	149.02%	387.78%	94.72%	204.25%	-152.49%
Invested Capital Growth	7,501.69%	-127.73%	-65.97%	29.54%	-116.65%	-86.66%	-50.94%	-33.58%	-67.79%	1,129.24%
Revenue Q/Q Growth	12.81%	13.78%	13.91%	8.93%	4.06%	-41.42%	126.19%	-37.59%	164.00%	-56.25%
EBITDA Q/Q Growth	0.37%	130.52%	-406.88%	73.69%	-490.85%	-106.71%	313.22%	-377.15%	130.69%	-1,838.85%
EBIT Q/Q Growth	-214.34%	117.34%	-266.88%	65.07%	-317.88%	-111.70%	284.81%	-565.81%	118.79%	-116.04%
NOPAT Q/Q Growth	-30.88%	131.01%	-266.88%	59.86%	-263.69%	-109.88%	318.91%	-267.02%	152.41%	-116.04%
Net Income Q/Q Growth	-195.37%	120.62%	-274.97%	64.05%	-289.64%	-112.70%	271.39%	-391.67%	129.95%	-95.44%
EPS Q/Q Growth	0.00%	116.67%	-300.00%	0.00%	0.00%	-111.11%	280.00%	0.00%	0.00%	-100.00%
Operating Cash Flow Q/Q Growth	-125.91%	135.22%	150.75%	-739.02%	-55.67%	-87.71%	558.85%	-154.51%	266.76%	-169.20%
Free Cash Flow Firm Q/Q Growth	-3,015.87%	209.97%	14.69%	-161.91%	-28.35%	-37.36%	2,035.40%	-103.44%	217.42%	-267.71%
Invested Capital Q/Q Growth	25,456.77%	-136.39%	-88.96%	826.74%	-194.99%	-55.35%	-57.97%	-6.61%	-23.85%	64.15%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.60%	61.04%	62.00%	62.85%	49.64%	62.65%	80.70%	63.08%	74.84%	62.69%
EBITDA Margin	6.97%	7.84%	-29.22%	-6.57%	-26.50%	-4.67%	40.74%	-43.21%	9.73%	-83.72%
Operating Margin	5.40%	4.93%	-32.35%	-10.04%	-27.25%	-7.80%	32.37%	-47.78%	12.50%	-89.93%
EBIT Margin	-5.00%	4.93%	-32.35%	-10.04%	-31.31%	-7.80%	39.03%	-47.78%	6.40%	-89.93%
Profit (Net Income) Margin	-5.13%	6.07%	-33.51%	-10.18%	-30.85%	-8.24%	38.00%	-50.15%	10.73%	-94.59%
Tax Burden Percent	117.03%	125.15%	101.81%	100.00%	112.29%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	87.80%	98.43%	101.77%	101.38%	87.73%	105.66%	97.35%	104.97%	167.65%	105.18%
Effective Tax Rate	0.00%	-25.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	7.61%	1,059.23%	-846.86%	-70.53%	-454.03%	-75.47%	493.80%	-218.46%	40.56%	-627.41%
ROIC Less NNEP Spread (ROIC-NNEP)	190.89%	1,059.29%	-839.94%	-68.01%	-447.38%	-73.80%	488.63%	-208.13%	42.27%	-618.58%
Return on Net Nonoperating Assets (RNNOA)	-5.42%	-1,046.27%	793.25%	50.62%	405.72%	61.32%	-426.61%	145.04%	-24.24%	531.42%
Return on Equity (ROE)	2.19%	12.96%	-53.61%	-19.92%	-48.31%	-14.16%	67.19%	-73.42%	16.32%	-95.99%
Cash Return on Invested Capital (CROIC)	-105.98%	0.00%	-425.17%	-13.26%	0.00%	231.38%	50.54%	-66.69%	14.24%	-243.53%
Operating Return on Assets (OROA)	-3.61%	5.08%	-32.35%	-12.59%	-34.91%	-9.65%	41.97%	-49.43%	5.18%	-70.44%
Return on Assets (ROA)	-3.71%	6.25%	-33.52%	-12.76%	-34.39%	-10.20%	40.86%	-51.89%	8.69%	-74.09%
Return on Common Equity (ROCE)	2.19%	12.96%	-53.61%	-19.92%	-48.31%	-14.16%	67.19%	-73.42%	16.32%	-95.99%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-34.30%	-49.67%	5.89%	0.00%	13.21%	-1.40%	-56.50%	0.00%	-79.55%
Net Operating Profit after Tax (NOPAT)	0.44	0.64	-2.05	-0.56	-1.40	-0.38	3.88	-1.77	1.06	-2.03
NOPAT Margin	3.78%	6.17%	-22.64%	-7.03%	-19.08%	-5.46%	32.37%	-33.44%	12.50%	-62.95%
Net Nonoperating Expense Percent (NNEP)	-183.28%	-0.06%	-6.92%	-2.52%	-6.65%	-1.68%	5.17%	-10.33%	-1.70%	-8.83%
Return On Investment Capital (ROIC_SIMPLE)	0.81%	-	-	-	-6.69%	-	-	-	5.45%	-
Cost of Revenue to Revenue	44.40%	38.96%	38.00%	37.15%	50.36%	37.35%	19.30%	36.92%	25.16%	37.31%
SG&A Expenses to Revenue	57.68%	51.22%	61.62%	64.73%	62.57%	61.70%	38.96%	100.77%	51.24%	129.51%
R&D to Revenue	-7.48%	4.89%	32.73%	8.17%	14.32%	8.75%	9.38%	10.09%	11.11%	23.11%
Operating Expenses to Revenue	50.20%	56.11%	94.35%	72.90%	76.89%	70.45%	48.34%	110.86%	62.34%	152.63%
Earnings before Interest and Taxes (EBIT)	-0.58	0.51	-2.94	-0.80	-2.29	-0.55	4.68	-2.53	0.54	-2.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.81	0.81	-2.65	-0.52	-1.94	-0.33	4.89	-2.29	0.83	-2.70
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	14.09	9.70	6.28	6.22	7.26	6.33	5.32	8.72	5.45	4.75
Price to Tangible Book Value (P/TBV)	0.00	15.31	11.52	10.58	10.47	8.44	7.22	14.70	8.57	8.56
Price to Revenue (P/Rev)	8.82	4.47	2.69	2.81	3.55	3.26	3.07	4.02	3.36	2.82
Price to Earnings (P/E)	0.00	0.00	0.00	105.51	0.00	47.93	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.95%	0.00%	2.09%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.13	0.00	167.81	21.95	0.00	162.15	58.74	30.13	19.26	11.01
Enterprise Value to Revenue (EV/Rev)	9.20	4.01	2.28	2.47	3.05	2.76	2.53	3.68	2.89	2.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	40.37	292.94	29.30	101.15	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	81.05	0.00	42.26	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	198.54	0.00	48.65	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	370.50	65.48	1,702.05	14.38	14.14	9.78	10.99	43.78	12.75	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	33.39	16.50	76.51	0.00	65.93	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.22	0.26	0.35	0.32	0.35	0.34	0.36	0.57	0.49	0.57
Long-Term Debt to Equity	1.22	0.00	0.00	0.00	0.00	0.25	0.27	0.45	0.41	0.51
Financial Leverage	-0.03	-0.99	-0.94	-0.74	-0.91	-0.83	-0.87	-0.70	-0.57	-0.86
Leverage Ratio	2.70	2.05	2.08	2.05	1.99	1.89	1.80	1.91	1.71	1.79
Compound Leverage Factor	2.37	2.02	2.12	2.08	1.74	2.00	1.75	2.01	2.87	1.89
Debt to Total Capital	54.96%	20.52%	25.71%	24.47%	25.79%	25.35%	26.70%	36.44%	32.92%	36.35%
Short-Term Debt to Total Capital	0.00%	20.52%	25.71%	24.47%	25.79%	6.81%	6.75%	7.57%	5.30%	4.03%
Long-Term Debt to Total Capital	54.96%	0.00%	0.00%	0.00%	0.00%	18.55%	19.95%	28.87%	27.62%	32.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	45.04%	79.48%	74.29%	75.53%	74.21%	74.65%	73.30%	63.56%	67.08%	63.65%
Debt to EBITDA	-19.20	-0.96	-0.86	2.39	16.35	1.85	8.38	-1.50	-0.90	-0.95
Net Debt to EBITDA	-9.58	3.75	2.40	-5.55	-48.66	-5.28	-21.28	1.92	1.39	1.04
Long-Term Debt to EBITDA	-19.20	0.00	0.00	0.00	0.00	1.36	6.26	-1.19	-0.76	-0.84
Debt to NOPAT	-16.40	-1.13	-1.06	11.77	-6.45	3.08	-17.98	-1.61	-1.11	-1.14
Net Debt to NOPAT	-8.18	4.42	2.97	-27.27	19.19	-8.77	45.67	2.07	1.71	1.25
Long-Term Debt to NOPAT	-16.40	0.00	0.00	0.00	0.00	2.25	-13.44	-1.28	-0.93	-1.01
Altman Z-Score	2.83	1.84	-1.03	0.39	0.72	1.49	1.26	-0.30	-0.62	-2.60
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.06	1.51	1.40	1.59	1.65	2.61	2.75	2.55	3.10	3.52
Quick Ratio	1.02	1.31	1.24	1.37	1.53	2.46	2.57	2.35	2.81	3.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-39	1.35	-1.23	-1.44	2.33	3.25	5.18	-0.27	7.78	-6.62
Operating Cash Flow to CapEx	-6,375.00%	0.00%	0.00%	-17,664.29%	0.00%	0.00%	0.00%	0.00%	23,666.67%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-44.15
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.35
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.35
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.72	1.03	1.00	1.25	1.11	1.24	1.08	1.03	0.81	0.78
Accounts Receivable Turnover	8.89	7.63	7.89	9.64	12.02	13.15	14.81	13.29	5.80	20.02
Inventory Turnover	1.93	9.44	8.82	8.41	14.42	11.80	11.30	16.98	12.53	12.77
Fixed Asset Turnover	848.07	976.82	689.69	607.15	486.80	591.48	436.36	295.50	227.28	182.09
Accounts Payable Turnover	5.19	6.42	5.74	6.63	5.86	6.53	4.23	4.78	3.92	2.41
Days Sales Outstanding (DSO)	41.04	47.82	46.27	37.85	30.36	27.76	24.64	27.47	62.89	18.23
Days Inventory Outstanding (DIO)	188.85	38.65	41.39	43.41	25.32	30.94	32.29	21.49	29.14	28.58
Days Payable Outstanding (DPO)	70.37	56.85	63.63	55.09	62.33	55.86	86.29	76.34	93.18	151.74
Cash Conversion Cycle (CCC)	159.52	29.62	24.04	26.17	-6.66	2.84	-29.35	-27.38	-1.16	-104.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	39	-0.16	0.43	3.86	-0.53	0.56	1.25	2.98	3.19	4.19
Invested Capital Turnover	2.01	171.67	37.40	10.03	23.80	13.83	15.26	6.53	3.25	9.97
Increase / (Decrease) in Invested Capital	40	-0.71	-0.83	0.88	-3.72	-3.63	-1.30	-1.51	-6.71	4.60
Enterprise Value (EV)	359	139	71	85	96	91	74	90	61	46
Market Capitalization	344	155	85	96	112	107	89	98	71	53
Book Value per Share	$0.95	$0.62	$0.52	$0.60	$0.60	$0.66	$0.66	$0.44	$0.52	$0.44
Tangible Book Value per Share	($0.40)	$0.39	$0.29	$0.35	$0.42	$0.49	$0.48	$0.26	$0.33	$0.25
Total Capital	54	20	18	21	21	23	23	18	19	18
Total Debt	30	4.13	4.66	5.02	5.38	5.74	6.09	6.45	6.42	6.39
Total Long-Term Debt	30	0.00	0.00	0.00	0.00	4.20	4.55	5.11	5.38	5.68
Net Debt	15	-16	-13	-12	-16	-16	-15	-8.26	-9.89	-6.99
Capital Expenditures (CapEx)	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.14	-6.12	-5.82	-2.67	-5.41	-3.77	-3.28	-1.75	-1.73	-0.91
Debt-free Net Working Capital (DFNWC)	21	14	12	14	16	18	18	13	15	12
Net Working Capital (NWC)	21	10	7.22	8.96	11	17	17	12	14	12
Net Nonoperating Expense (NNE)	1.04	0.01	0.99	0.25	0.86	0.20	-0.68	0.89	0.15	1.02
Net Nonoperating Obligations (NNO)	15	-16	-13	-12	-16	-16	-15	-8.26	-9.89	-6.99
Total Depreciation and Amortization (D&A)	1.39	0.30	0.28	0.28	0.35	0.22	0.20	0.24	0.28	0.20
Debt-free, Cash-free Net Working Capital to Revenue	15.73%	-17.65%	-18.54%	-7.79%	-17.10%	-11.47%	-11.31%	-7.16%	-8.14%	-4.83%
Debt-free Net Working Capital to Revenue	54.02%	40.78%	37.84%	40.76%	50.50%	55.76%	63.01%	53.17%	68.59%	66.15%
Net Working Capital to Revenue	54.02%	28.88%	23.00%	26.13%	33.49%	51.07%	57.71%	47.68%	63.73%	62.40%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	$0.02	($0.12)	($0.03)	($0.10)	($0.02)	$0.18	($100.00)	$209.82	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	25.90M	25.90K	25.78M	25.76M	25.65M	25.72M	25.59M	25.53M	25.15M	25.37M
Adjusted Diluted Earnings per Share	$0.00	$0.02	($0.12)	($0.03)	$0.00	($0.02)	$0.18	$0.00	$0.00	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	26.82M	26.55K	25.78M	25.76M	25.69M	25.72M	25.98M	25.50M	25.46M	25.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.82M	25.84M	25.84M	25.69M	25.69M	25.66M	25.65M	25.50M	25.46M	25.30M
Normalized Net Operating Profit after Tax (NOPAT)	0.44	0.36	-2.05	-0.56	-1.40	-0.38	2.72	-1.77	0.74	-2.03
Normalized NOPAT Margin	3.78%	3.45%	-22.64%	-7.03%	-19.08%	-5.46%	22.66%	-33.44%	8.75%	-62.95%
Pre Tax Income Margin	-4.39%	4.85%	-32.92%	-10.18%	-27.47%	-8.24%	38.00%	-50.15%	10.73%	-94.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-19.30
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-13.51
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-19.30
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-13.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Eton Pharmaceuticals' Financials

When does Eton Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Eton Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Eton Pharmaceuticals' net income changed over the last 2 years?

Eton Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$3.82 million in 2024, falling from -$9.02 million in 2022. The previous period was -$936 thousand in 2023. See where experts think Eton Pharmaceuticals is headed by visiting Eton Pharmaceuticals' forecast page.

What is Eton Pharmaceuticals's operating income?

Eton Pharmaceuticals's total operating income in 2024 was -$2.60 million, based on the following breakdown:

Total Gross Profit: $23.41 million
Total Operating Expenses: $26.01 million

How has Eton Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' total revenue changed from $21.25 million in 2022 to $39.01 million in 2024, a change of 83.6%.

How much debt does Eton Pharmaceuticals have?

Eton Pharmaceuticals' total liabilities were at $51.70 million at the end of 2024, a 217.9% increase from 2023, and a 332.5% increase since 2022.

How much cash does Eton Pharmaceuticals have?

In the past 2 years, Eton Pharmaceuticals' cash and equivalents has ranged from $14.94 million in 2024 to $21.39 million in 2023, and is currently $14.94 million as of their latest financial filing in 2024.

How has Eton Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' book value per share changed from 0.52 in 2022 to 0.95 in 2024, a change of 82.9%.

Related Companies

This page (NASDAQ:ETON) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Financials

Frequently Asked Questions About Eton Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Financials

Annual Income Statements for Eton Pharmaceuticals

Quarterly Income Statements for Eton Pharmaceuticals

Annual Cash Flow Statements for Eton Pharmaceuticals

Quarterly Cash Flow Statements for Eton Pharmaceuticals

Annual Balance Sheets for Eton Pharmaceuticals

Quarterly Balance Sheets for Eton Pharmaceuticals

Annual Metrics And Ratios for Eton Pharmaceuticals

Quarterly Metrics And Ratios for Eton Pharmaceuticals

Frequently Asked Questions About Eton Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools